|1.||Zhang, J: 2 articles (12/2001 - 10/2000)|
|2.||Zhang, X: 2 articles (12/2001 - 10/2000)|
|3.||Chen, P: 2 articles (12/2001 - 10/2000)|
|4.||Hara, S: 1 article (07/2001)|
|5.||Arakawa, S: 1 article (07/2001)|
|6.||Kamidono, S: 1 article (07/2001)|
|7.||Miyake, H: 1 article (07/2001)|
|8.||Hara, I: 1 article (07/2001)|
|9.||Kulozik, A E: 1 article (11/2000)|
|10.||Sinha, P: 1 article (11/2000)|
|1.||beta-Thalassemia (Cooley's Anemia)
02/01/2000 - "Oral isobutyramide therapy in patients with thalassemia intermedia: results of a phase II open study."
11/15/2000 - "Oral isobutyramide reduces transfusion requirements in some patients with homozygous beta-thalassemia."
02/01/2000 - "Testing of the effects of different schedules of administration of isobutyramide will be required in order to determine the optimal use of this compound in the treatment of the beta-thalassemia syndromes."
12/01/2001 - "Our results have further proved the potential value of isobutyramide in treatment of beta-thalassemia and sickle cell disease."
10/01/2000 - "This function, together with the advantages of nontoxic and long halflife makes isobutyramide a promising application in the treatment of beta-thalassemia and sickle cell anemia."
06/01/1998 - "Decreased tumor cell proliferation and increased PSA gene expression induced by isobutyramide results in disconcordant changes in serum PSA and tumor volume and reduces the utility of serum PSA as a marker of response to therapy."
06/01/1998 - "The effects of isobutyramide on LNCaP tumor growth and serum PSA levels in both intact and castrate male mice were compared to controls. "
07/01/2001 - "Oral administration of isobutyramide significantly reduced the KoTCC-1/C tumor volume compared with the KoTCC-1/BH tumor volume in nude mice. "
06/01/1998 - "The combination of castration and adjuvant isobutyramide was synergistic in delaying tumor progression. "
06/01/1998 - "Isobutyramide treatment induced pronounced morphological changes in LNCaP tumor cells, with loss of defined nucleoli and dispersion of chromatin distribution. "
|3.||Prostatic Neoplasms (Prostate Cancer)
06/01/1998 - "The objectives of this study were to characterize the in vitro effects of sodium butyrate on human prostate cancer cell growth, PSA gene expression, and differentiation in the LNCaP tumor model and to determine whether tumor progression in vivo is delayed by isobutyramide, an orally bioavailable butyrate analogue with a longer half-life. "
|4.||Urinary Bladder Neoplasms (Bladder Cancer)
07/01/2001 - "These findings suggest that isobutyramide therapy could be a novel therapeutic strategy for patients with bladder cancer if docetaxel is combined according to the Bcl-2 expression status."
07/01/2001 - "The objectives of our study were to characterize the in vitro effects of NaBt and/or docetaxel on the growth, cell cycle and apoptosis of human bladder cancer cells, and to determine whether tumor growth in vivo is inhibited by isobutyramide, an orally bioavailable Bt analogue, and/or docetaxel by using Bcl-2-transfected human bladder cancer cell line KoTCC-1/BH and control vector only-transfected cell line KoTCC-1/C. "
07/01/1996 - "VX-366 (isobutyramide) is an orally available branched chain amide that may offer an alternative to current treatments for beta-hemoglobinopathy. "
11/15/2000 - "The butyrate derivative isobutyramide (IBT) increases fetal hemoglobin (HbF) in patients with beta-hemoglobinopathies, but little is known about its usefulness for prolonged therapeutic use. "
06/01/1999 - "Pharmacologic agents such as hydroxyurea (HU), N, 3-4 trihydroxybenzamide (didox), and isobutyramide (ISB) can elevate gamma-globin as a potential treatment for the beta-hemoglobinopathies. "
|1.||Fetal Hemoglobin (Hemoglobin F)
|3.||Butyric Acid (Butanoic Acid)
|10.||A 7 (A-7)